Condition 1: Breast Cancer. Condition 2: Breast Cancer. Condition 3: Breast Cancer. Condition 4: Breast Cancer. Condition 5: Breast Cancer. Condition 6: Breast Cancer. Condition 7: Breast Cancer. Condition 8: Breast Cancer. Malignant neoplasm: overlapping lesion of breast Malignant neoplasm: upper-inner quadrant of breast Malignant neoplasm: lower-inner quadrant of breast Malignant neoplasm: upper-outer quadrant of breast Malignant neoplasm: lower-outer quadrant of breast Malignant neoplas
Conditions
Interventions
Intervention 1: The intervention group will receive 1500 mg/day (three 500 mg tablets/day) of Glucuronic acid orally for 12 weeks. The Glucuronic acid produced from the decomposition of Alginate powde
Treatment - Drugs
Control group will receive of conventional drugs orally for 12 weeks.
The intervention group will receive 1500 mg/day (three 500 mg tablets/day) of Glucuronic acid orally for 12 weeks. The Glucuronic acid produced from the decomposition of Alginate powder (a safe, natur
Sponsors
Vice-Chancellor for Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
65 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 30-60 years old patients, Diagnosed with breast cancer according to American College of oncology Diagnostic Criteria after the initial visit by a specialist in cancer surgery and parameters CEA, CA15.3, CBC and sonography, Each patient must sign written informed consent. Exclusion Criteria: History of fever and Infectious diseases, Positive pregnancy test or Lactation, Other collagen- vascular and auto immune diseases, Patients have enrolled another clinical trial study within last 4 weeks, Other concomitant diseases (Hepatic, renal, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feel the mass and tenacity in breast. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Examination by specialist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor size. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Abbas Mirshafiey
Department of pathobiology, School of Public Health, Tehran University of Medical Sciences
Outcome results
None listed